Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Isis Pharmaceuticals Inc.

(ISIP)

Wedbush Morgan analyst Fariba Ghodsian initiated coverage with a "buy" recommendation and a 12-month price target of $9-10.

Ghodsian said the Carlsbad, Calif., company has

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE